Papain and related enzymes in OPAL-A lose their activity in the presence of water and become inactive within weeks. It is the enzymatic activity of papain that brings about debridement and wound healing. However, neither papain nor bromelain preparations have fulfilled their potential due to the instability of their enzymatic activity.
The ProteoActiv™ technology involves both chemical and physical processes to modify the active. In an in-vitro industry-standard model of enzymatic activity, the ProteoActiv™ technology enhanced, by approximately 6-fold, and stabilised the activity of papain, bromelain and OPAL-A at room temperature. The duration of the study was 50 days. Longer studies are planned.
The ProteoActiv™ technology has the potential to solve the stability challenge that has prevented wider use of commercial papain and bromelain in the clinical setting.
A provisional patent application for the ProteoActiv™ technology was filed with IP Australia on 11 October 2018. An international-type search was conducted in November 2018, which confirmed that the majority of claims in the patent application, according to the examiner, were reasoned to show novelty, inventive steps and industrial application.
Proteolytics is considering opportunities for co-development and out-licensing of its ProteoActiv™ technology to pharmaceutical companies with short-acting enzymatic debriding agents currently on market.